Further re AIVLOSIN

24 April 2006
                                  Lawrence plc
       ECO Animal Health - Receipt of further Aivlosin approvals in Europe

On  22  March  2006  Lawrence plc announced that the  Committee  for  Veterinary
Medicinal Products (CVMP) of The European Agency for the Evaluation of Medicinal
Products  (EMEA)  would  meet  in late April. At that  meeting  the  CVMP  would
consider, amongst others, two Aivlosin applications for the treatment of enteric
(digestive)  diseases  in pigs submitted by ECO Animal Health  (ECO),  a  wholly
owned subsidiary of Lawrence plc.

Lawrence is delighted to report that ECO has now received positive opinions from
the  CVMP on these two applications, which are for the treatment of ileitis  and
swine  dysentery.  ECO can shortly commence the marketing  of  Aivlosin  in  the
European Union for these conditions.

These  approvals  represent a significant increase in  the  potential  available
market  for  Aivlosin  in the EU and the Group expects that  they  will  be  the
catalyst  for  a significant marketing initiative to be launched  by  its  major
distributor, Schering Plough.  Further EU marketing authorisations for  Aivlosin
in both swine and poultry are being progressed.

Peter Lawrence, Chairman of Lawrence plc, commented:
"These  approvals  represent a further significant  step  in  the  marketing  of
Aivlosin  in Europe. Obtaining registrations is an essential but costly  process
involving extensive trial work and lengthy evaluation periods; we will  need  to
invest  significant  sums  to  ensure that all our pharmaceutical  products  are
brought to market as quickly and efficiently as possible"


Contacts:

Peter Lawrence
Chairman, Lawrence plc
020 8336 2900

Anthony Spiro
Spiro Financial
020 8949 0428

Philip Davies
Charles Stanley Securities
020 7953 2457

Notes to Editors:
Lawrence  plc  is  a leader in the development, manufacture and distribution  of
principally  specialist  chemical and pharmaceutical  products  for  the  animal
health  and  farming  markets worldwide. Our products for these  growth  markets
incorporate  natural  ingredients to promote well being and  sustainability.  We
achieve  our financial goals through the careful and responsible application  of
science to generate value for our shareholders.